EP12.02-01 Novel-Acquired KANK1-ALK Fusion in An Advanced Lung Adenocarcinoma Responds to Alectinib: A Case Report

More than 90 distinct fusion partners of anaplastic lymphoma kinase (ALK) rearrangement have been identified. Different ALK fusions may exhibit different sensitivities to ALK tyrosine kinase inhibitors (TKIs). The emergence of rare fusions raises great challenges to targeted therapies.